scholarly article | Q13442814 |
P356 | DOI | 10.1038/NRGASTRO.2013.182 |
P698 | PubMed publication ID | 24061205 |
P50 | author | Quentin M Anstee | Q42834905 |
P2093 | author name string | Christopher P Day | |
P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits | Q22066284 | ||
Finding the missing heritability of complex diseases | Q22122198 | ||
Finishing the euchromatic sequence of the human genome | Q22122488 | ||
Are rare variants responsible for susceptibility to complex diseases? | Q22337172 | ||
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease | Q22337234 | ||
Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities | Q24303914 | ||
Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis | Q24319960 | ||
Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD) | Q24535745 | ||
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls | Q24550675 | ||
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease | Q24611284 | ||
Biological, clinical and population relevance of 95 loci for blood lipids | Q24622541 | ||
Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants | Q24633806 | ||
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans | Q24643492 | ||
A second generation human haplotype map of over 3.1 million SNPs | Q24651939 | ||
The TDT and other family-based tests for linkage disequilibrium and association | Q24675685 | ||
A haplotype map of the human genome | Q24679827 | ||
The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad | Q27641368 | ||
The International HapMap Project | Q27860695 | ||
Characterization of the human patatin-like phospholipase family | Q28248355 | ||
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
Newly identified loci that influence lipid concentrations and risk of coronary artery disease | Q28264535 | ||
The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population | Q28295369 | ||
I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease | Q42963113 | ||
Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. | Q43014565 | ||
The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. | Q43024330 | ||
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. | Q43107476 | ||
Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent | Q43257949 | ||
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. | Q43565987 | ||
Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. | Q44030028 | ||
The utility of radiological imaging in nonalcoholic fatty liver disease. | Q44116674 | ||
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values | Q44458156 | ||
Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors | Q44508808 | ||
Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats | Q44583413 | ||
Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis | Q44849407 | ||
A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. | Q44851403 | ||
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis | Q45070082 | ||
A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease | Q45345284 | ||
Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins | Q46080116 | ||
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis | Q46080216 | ||
Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. | Q46117666 | ||
A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans | Q46118770 | ||
Ethnic differences in the prevalence of cryptogenic cirrhosis | Q46186734 | ||
Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults | Q46657358 | ||
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. | Q50878523 | ||
The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. | Q51410082 | ||
The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. | Q51529673 | ||
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study | Q51541188 | ||
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. | Q51732144 | ||
Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. | Q51757427 | ||
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. | Q53555710 | ||
Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. | Q53910016 | ||
Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. | Q54381048 | ||
Preoperative donor liver biopsy for adult living donor liver transplantation: Risks and benefits | Q57205222 | ||
A Germline DNA Polymorphism Enhances Alternative Splicing of theKLF6Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk | Q57540252 | ||
Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms | Q57659850 | ||
A position statement on NAFLD/NASH based on the EASL 2009 special conference | Q61338101 | ||
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies | Q62607244 | ||
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver | Q62607247 | ||
Liver biopsy findings from healthy potential living liver donors: Reasons for disqualification, silent diseases and correlation with liver injury tests | Q62617432 | ||
Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro | Q63408528 | ||
Genome-wide association studies: past, present and future | Q63916518 | ||
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds | Q73143340 | ||
One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation | Q78634574 | ||
Genomewide association studies--illuminating biologic pathways | Q83658310 | ||
How big a problem is non-alcoholic fatty liver disease? | Q84570168 | ||
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study | Q84760102 | ||
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity | Q28297290 | ||
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis | Q28943317 | ||
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis | Q29417041 | ||
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease | Q29417076 | ||
Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese | Q29417094 | ||
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
A HapMap harvest of insights into the genetics of common disease | Q29614875 | ||
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease | Q29614897 | ||
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults | Q29614911 | ||
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity | Q29614914 | ||
Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
Genetic mapping in human disease | Q29614943 | ||
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts | Q29614946 | ||
Genome-wide association studies for common diseases and complex traits | Q29615822 | ||
On the allelic spectrum of human disease | Q29616298 | ||
Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase | Q30032295 | ||
Epidemiology and natural history of non-alcoholic steatohepatitis | Q30449204 | ||
Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue | Q33359272 | ||
A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis | Q33673834 | ||
A feed-forward loop amplifies nutritional regulation of PNPLA3 | Q33842841 | ||
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits | Q33851563 | ||
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease | Q33937046 | ||
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease | Q34101263 | ||
Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease | Q34101705 | ||
Association study designs for complex diseases | Q34186026 | ||
Imaging of hepatic steatosis | Q34215183 | ||
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma | Q34224637 | ||
From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. | Q34365079 | ||
Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase | Q34369246 | ||
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease | Q34427653 | ||
Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. | Q34449398 | ||
Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome | Q34503398 | ||
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo | Q34546130 | ||
Genome-wide association studies: theoretical and practical concerns | Q34555195 | ||
Genomewide association studies and human disease | Q34606556 | ||
Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population | Q34618881 | ||
Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance | Q34674263 | ||
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease | Q34759018 | ||
Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes | Q34861754 | ||
AGA technical review on nonalcoholic fatty liver disease | Q34982453 | ||
Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study | Q35043760 | ||
Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans | Q35102868 | ||
Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease | Q35423296 | ||
A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents | Q35564927 | ||
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ | Q35649446 | ||
Ethnicity and nonalcoholic fatty liver disease | Q35754063 | ||
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents | Q35783993 | ||
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease | Q35809618 | ||
The epidemiology of fatty liver | Q35920748 | ||
Heritability of nonalcoholic fatty liver disease | Q36095663 | ||
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis | Q36357941 | ||
Multigenerational epigenetic adaptation of the hepatic wound-healing response | Q36374096 | ||
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. | Q36377266 | ||
Apoptosis and necrosis in the liver: a tale of two deaths? | Q36382247 | ||
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients | Q36727795 | ||
The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study | Q36807854 | ||
A common variant in the adiponutrin gene influences liver enzyme values | Q37137544 | ||
Ethnic differences in hepatic steatosis: an insulin resistance paradox? | Q37175282 | ||
Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent | Q37197345 | ||
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction | Q37255709 | ||
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. | Q37337449 | ||
Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity | Q37394350 | ||
Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene | Q37400771 | ||
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance | Q37552186 | ||
Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein | Q37756050 | ||
The importance of fatty liver disease in clinical practice | Q37766943 | ||
Genome-wide association studies: results from the first few years and potential implications for clinical medicine | Q37827862 | ||
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis | Q38090905 | ||
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis | Q39396087 | ||
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | Q39693472 | ||
Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease | Q39892915 | ||
The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver | Q42096203 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 645-655 | |
P577 | publication date | 2013-09-24 | |
P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
P1476 | title | The genetics of NAFLD | |
P478 | volume | 10 |
Q30412771 | 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics |
Q97526906 | A Description of Risk Factors for Non-alcoholic Fatty Liver Disease in the Southern Community Cohort Study: A Nested Case-Control Study |
Q38684906 | A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. |
Q57494349 | A systematic review of the present and future of non-alcoholic fatty liver disease |
Q37358301 | Altered microRNA-9 Expression Level is Directly Correlated with Pathogenesis of Nonalcoholic Fatty Liver Disease by Targeting Onecut2 and SIRT1. |
Q64120591 | An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian Biobank |
Q55323878 | Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. |
Q39279036 | Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults |
Q93095423 | Association between rs2303861 polymorphism in CD82 gene and non-alcoholic fatty liver disease: a preliminary case-control study |
Q35989613 | Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease |
Q92504908 | Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population |
Q35914994 | Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study |
Q61798368 | Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population |
Q49803699 | Biopsy Needle Integrated with Electrical Impedance Sensing Microelectrode Array towards Real-time Needle Guidance and Tissue Discrimination. |
Q38858403 | Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line. |
Q35948098 | Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. |
Q39487830 | Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. |
Q50350904 | Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. |
Q30392056 | Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. |
Q91089901 | Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Contributes to Hepatic Steatosis |
Q38788301 | Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts |
Q40147836 | Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. |
Q57463916 | Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis |
Q35337252 | Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. |
Q46577273 | Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers |
Q53762139 | Ectopic fat: a target for cardiometabolic risk management. |
Q33780166 | Effects of resveratrol and other polyphenols in hepatic steatosis. |
Q30400120 | Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field |
Q26822513 | Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition |
Q28079271 | Epigenetics in liver disease: from biology to therapeutics |
Q52599636 | Ethanol extract of Allium fistulosum inhibits development of non-alcoholic fatty liver disease. |
Q36438048 | Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese |
Q33886936 | Experimental models of non-alcoholic fatty liver disease in rats |
Q93028935 | Fatty Liver and the Forensic Pathologist |
Q74441335 | Fatty liver disease: The liver labyrinth |
Q55326372 | Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. |
Q52343193 | Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study. |
Q92863559 | Free fatty acid-induced histone acetyltransferase activity accelerates lipid accumulation in HepG2 cells |
Q89624033 | From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options |
Q62789007 | From Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: A Systems Understanding |
Q34800989 | From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations |
Q36411266 | Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population |
Q52644448 | Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). |
Q53817283 | Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome. |
Q61448416 | Genetic polymorphisms associated with nonalcoholic fatty liver disease in Uyghur population: a case-control study and meta-analysis |
Q34167128 | Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos |
Q92861535 | Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? |
Q45067817 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
Q92763088 | Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology |
Q40094359 | Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. |
Q44411962 | High-fat diet triggers Mallory-Denk body formation through misfolding and crosslinking of excess keratin 8. |
Q28074455 | How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? |
Q45061974 | Human germline hedgehog pathway mutations predispose to fatty liver. |
Q38951594 | Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing. |
Q58751826 | Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease |
Q38470686 | Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonalcoholic liver disease |
Q47615586 | Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. |
Q38365029 | Immunoregulation by lipids during the development of non-alcoholic steatohepatitis |
Q47744258 | Influence of dietary macronutrients on liver fat accumulation and metabolism. |
Q35704998 | Influence of the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and Renal Function among Normal Weight Subjects |
Q92089595 | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
Q47160560 | Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. |
Q36694213 | Kcne2 deletion causes early-onset nonalcoholic fatty liver disease via iron deficiency anemia |
Q47972230 | Lipid Droplet Biogenesis. |
Q52312629 | Liver Disease in a Residential Cohort with Elevated Polychlorinated Biphenyl Exposures. |
Q38924351 | Living with Fibrosis: From Diagnosis to Future Hope. |
Q44339679 | Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. |
Q91811722 | Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered |
Q90607848 | Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism |
Q54212460 | Meta-analysis reveals a specific association of the PNPLA3 I148M polymorphism with ALT level in adolescents. |
Q90031078 | Metabolic Targets in Nonalcoholic Fatty Liver Disease |
Q64071480 | Microbial Population Changes and Their Relationship with Human Health and Disease |
Q52323790 | NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects. |
Q87354153 | NAFLD. Metabolic make-up of NASH: from fat and sugar to amino acids |
Q38204542 | Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome |
Q87021168 | Non-alcoholic fatty liver disease: when to intervene and with what |
Q90416246 | Nonalcoholic Fatty Liver Disease |
Q33855157 | Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. |
Q89377158 | Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns |
Q38592767 | Nonalcoholic fatty liver disease - current status and future directions |
Q38430909 | Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms |
Q38956717 | Nonalcoholic fatty liver disease in Asia: emerging perspectives. |
Q27021161 | Nonalcoholic fatty liver disease: new treatments |
Q39072611 | Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review |
Q38606360 | Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. |
Q30244335 | Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease |
Q85335771 | Patatin-like phospholipase domain-containing protein 3 and liver disease: opportunities to unravel mechanisms underlying statistical associations |
Q35928495 | Pathogenesis of nonalcoholic steatohepatitis |
Q35965687 | Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease |
Q50207491 | Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease |
Q64355138 | Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease |
Q60918532 | RNA-seq analysis of hepatic gene expression of common Pekin, Muscovy, mule and hinny ducks fed ad libitum or overfed |
Q55359842 | Recent advances in understanding and managing non-alcoholic fatty liver disease. |
Q38665591 | Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines |
Q42003073 | Regional differences in genetic susceptibility to non-alcoholic liver disease in two distinct Indian ethnicities |
Q64899850 | Systems Analyses Reveal Physiological Roles and Genetic Regulators of Liver Lipid Species. |
Q26774883 | TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease |
Q34785862 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease |
Q64112009 | TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population |
Q57132035 | Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model |
Q39790741 | The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients |
Q26744380 | The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background |
Q53382915 | The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). |
Q51278231 | The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. |
Q44238213 | The global NAFLD epidemic |
Q92816978 | The influence of dietary fatty acids on liver fat content and metabolism |
Q38645975 | The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment |
Q39140524 | Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease |
Q37643487 | Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans |
Q34309870 | Variant adiponutrin confers genetic protection against cholestatic itch |
Q51761242 | p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. |
Q29144909 | p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer |
Search more.